Sincalide Peptide: Kinevac (CCK-8), Uses and Safety Limits
Sincalide peptide guide covering Kinevac (CCK-8) biology, FDA-approved diagnostic uses for gallbladder and pancreatic testing, reference dosing and safety limits.
Sincalide is a diagnostic peptide with a very different profile from the research-market peptides people often search for. It is a synthetically prepared C-terminal octapeptide of cholecystokinin, frequently abbreviated CCK-8, and it is sold in the United States as the FDA-approved injectable drug Kinevac. It is not a wellness compound, a growth peptide or a "gut health" supplement. It is a short-acting hormone analog given in a clinical setting to provoke a measurable physiologic response.
The point of sincalide is provocation, not therapy. Clinicians use it to make the gallbladder squeeze on command during nuclear imaging, to draw out a concentrated bile sample, or to push the pancreas to secrete so its output can be analyzed. Because its job is to trigger a transient response and then disappear, its pharmacology is defined by a very short half-life and a narrow diagnostic dose range, not by chronic dosing.
This guide is educational and not medical advice. Sincalide is a prescription diagnostic administered by trained personnel under medical supervision, with resuscitation support available. Nothing here is a protocol.
For related context on gut and hormone-signaling peptides, compare this guide with octreotide, linaclotide, teduglutide, what peptides are and the peptide half-life guide, which is especially relevant here because sincalide's biology is dominated by how fast it clears.
Sincalide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic C-terminal octapeptide of cholecystokinin (CCK-8), sold as Kinevac. |
| Drug class | A cholecystopancreatic-gastrointestinal hormone analog used as a diagnostic agent. |
| Approval | FDA-approved, initial US approval 1976; current label held by Bracco Diagnostics. |
| Route | Intravenous only, as a slow bolus or a timed infusion. |
| Main effect | Stimulates gallbladder contraction, sphincter of Oddi relaxation and pancreatic secretion. |
| Half-life | Very short; the label cites a serum half-life of roughly 2.5 minutes. |
| Evidence type | FDA label, pharmacology data, and nuclear-medicine methodology trials. |
How Sincalide Works
Cholecystokinin is a natural gut hormone released after a meal, especially in response to fat and protein. It tells the gallbladder to contract and empty stored bile into the intestine, signals the sphincter of Oddi to relax so bile can pass, and prompts the pancreas to release digestive enzymes. Sincalide is the active C-terminal eight–amino-acid fragment of that hormone, so it reproduces those effects when given intravenously.
At the receptor level, sincalide acts on cholecystokinin receptors. The CCK-A receptor (also called CCK1), which predominates in the gallbladder and pancreas, drives the contraction and secretion that the test relies on. The related CCK-B/gastrin receptor family sits more in the stomach and central nervous system. Because sincalide hits the same targets as endogenous CCK, a single controlled dose produces a controlled, observable contraction rather than the slow, food-driven response of normal digestion.
The Kinevac label reports that maximal gallbladder contraction occurs within about 5 to 15 minutes of a bolus injection. The peptide is then cleared quickly: the label cites a serum half-life on the order of 2.5 minutes, and published volunteer pharmacokinetics have measured values close to 1.3 minutes. That rapid clearance is a feature, not a flaw, because it lets the gallbladder relax again and even allows a second dose within the same study if needed.
Approved Diagnostic Uses
Sincalide is approved as a diagnostic tool, and the labeled indications are narrow and specific. Per the Kinevac prescribing information, it is indicated in adults to:
| Approved use | What the source supports | Important limit |
|---|---|---|
| Stimulate gallbladder contraction | Provoke contraction for diagnostic imaging (such as HIDA/cholescintigraphy) or to obtain concentrated bile by duodenal aspiration. | It assesses function; it is not a treatment for gallbladder disease. |
| Stimulate pancreatic secretion | Used in combination with secretin before a duodenal aspirate to analyze enzyme activity, composition and cytology. | Requires the paired secretin protocol, not sincalide alone. |
| Accelerate barium transit | Speed a barium meal through the small bowel to reduce examination time and radiation exposure. | A niche radiographic adjunct, not a routine use. |
The flagship clinical application is sincalide-stimulated cholescintigraphy, where the peptide is given during a hepatobiliary scan to calculate the gallbladder ejection fraction (GBEF) — the percentage of bile the gallbladder expels after stimulation. A low GBEF can support a diagnosis such as chronic acalculous cholecystitis or biliary dyskinesia, though imaging is always read in clinical context.
What The Evidence Shows, And Its Limits
The strongest sincalide evidence is methodological. The central problem in practice is that how you give the dose changes the result. A fast bolus tends to cause cramping and can produce an artificially low ejection fraction, because rapid, non-physiologic stimulation makes the gallbladder behave abnormally. This made early "normal" values inconsistent between sites.
A multicenter investigation published in the Journal of Nuclear Medicine (Ziessman and colleagues, 2010) studied 60 healthy subjects and compared different infusion durations for the same 0.02 mcg/kg total dose. It concluded that a 60-minute infusion, with the ejection fraction calculated at 60 minutes, was the optimal method, giving the lowest variability and the best-defined normal range, with a lower limit of normal of 38%. Interdisciplinary consensus recommendations later reinforced standardized, slower infusion protocols over the historical rapid bolus.
The honest limit is that sincalide is a provocation agent, not a stand-alone diagnosis. A GBEF number depends heavily on technique, the exact dose, recent meals, medications and patient factors. Compounded versus proprietary sincalide preparations have also been compared in the literature because supply and formulation differences can affect results. None of this evidence supports any use of sincalide outside a controlled diagnostic exam, and there is no established role for it as an ongoing therapy.
Safety Limits
Sincalide's safety profile follows from its mechanism and from its sulfite- containing formulation. The effects are usually brief, but some are serious.
| Safety issue | Why it matters |
|---|---|
| Sulfite hypersensitivity | The formulation contains sodium metabisulfite, which can trigger allergic and asthmatic reactions in susceptible people. |
| Anaphylaxis | Postmarketing reports include anaphylaxis and anaphylactic shock during or within an hour of dosing; resuscitation support must be available. |
| Pregnancy harm | Sincalide can cause uterine contractions; the label warns of preterm labor and spontaneous abortion, so it is avoided in pregnancy. |
| Gastrointestinal effects | Rapid IV injection commonly causes nausea, vomiting and abdominal cramping; slower infusion reduces this. |
| Gallstone movement | Forced contraction could push a stone into the bile ducts in patients who have stones. |
| Other serious events | Reported reactions include hypotension, syncope and seizures. |
The most common adverse reactions reported on the label are abdominal discomfort or pain and nausea. Contraindications include known hypersensitivity to sincalide or sulfites and intestinal obstruction. The very short half-life limits how long most effects persist, but it does not reduce the need for monitoring during and shortly after administration.
How To Evaluate A Sincalide Claim
Because sincalide occasionally appears in non-clinical "peptide" discussions, it helps to apply a quick filter.
First, is the use diagnostic? Legitimate sincalide use is a one-time, in-clinic provocation for imaging or sampling. Any framing as a recurring treatment, digestion booster or wellness peptide is a red flag.
Second, is the route correct? Sincalide is intravenous only. Suggestions of oral, subcutaneous or at-home dosing do not match the approved drug. Other gut-active peptides illustrate how route is mechanism-specific: linaclotide is an oral, minimally absorbed intestinal agent, while octreotide is an injected somatostatin analog used to suppress secretion — close to the opposite of what sincalide does.
Third, is the dose plausibly diagnostic? Reference doses are tiny and weight- based (microgram-per-kilogram), given over defined minutes. Anything resembling a "course" or escalating protocol is inconsistent with the label.
Fourth, does the source acknowledge technique sensitivity and safety (sulfites, pregnancy, anaphylaxis)? Sources that skip these are not describing real clinical use.
Bottom Line
Sincalide is a real, FDA-approved peptide drug, but its role is narrow and diagnostic. As the synthetic CCK-8 fragment Kinevac, it provokes gallbladder contraction and pancreatic secretion so clinicians can image function, sample bile or analyze pancreatic output. Its biology is defined by rapid action and a very short half-life, which is exactly what a provocation agent needs.
The same facts set its limits. Sincalide is intravenous-only, dosed in micrograms per kilogram under supervision, sensitive to infusion technique, and carries real risks including sulfite hypersensitivity, anaphylaxis and pregnancy harm. It is not a therapeutic peptide, not a supplement and not something with established at-home or chronic dosing. Read any sincalide claim through the lens of a controlled diagnostic test, and it stops being confusing.
References
DailyMed. Kinevac (sincalide) injection, prescribing information.
US FDA. Kinevac (sincalide for injection) full prescribing information (label PDF).
Ziessman HA, et al. Sincalide-stimulated cholescintigraphy: a multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. J Nucl Med. 2010.
Tulchinsky M, et al. Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. Clin Gastroenterol Hepatol. 2011.
Rastogi A, et al. Cholecystokinin Test. StatPearls, NCBI Bookshelf.
NCATS Inxight Drugs. Sincalide drug record.
Ziessman HA, et al. Normal values for sincalide cholescintigraphy: comparison of two methods. Radiology. 2001.
Krishnamurthy GT, Krishnamurthy S. Gallbladder response to a second dose of cholecystokinin during the same imaging study. Eur J Nucl Med.